Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Kala Pharmaceuticals Inc.
DescriptionAcyclovir delivered using mucus-penetrating nanoparticles
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationHerpes simplex virus (HSV)
Indication DetailsPrevent herpes simplex virus (HSV) type 2 infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today